期刊
OPEN BIOLOGY
卷 13, 期 5, 页码 -出版社
ROYAL SOC
DOI: 10.1098/rsob.220370
关键词
Parkinson's disease; NO; 7-NI; dyskinesias; L-DOPA
This study aimed to determine whether the nitric oxide synthase inhibitor, 7-nitroindazole (7-NI), can reduce L-DOPA-induced dyskinesias (LIDs) in a non-human primate model of Parkinson disease (PD). The results showed that the dyskinetic monkeys treated with 7-NI had a significant decrease in LIDs compared to their scores without 7-NI treatment. However, the anti-Parkinsonian effect of L-DOPA remained unchanged. This study suggests that 7-NI could be a promising therapy to improve the quality of life of PD patients.
Nitric oxide (NO) plays a pivotal role in integrating dopamine transmission in the basal ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). The objective of this study was to ascertain whether the NO synthase inhibitor, 7-nitroindazole (7-NI), is able to reduce L-DOPA-induced dyskinesias (LIDs) in a non-human primate model of PD chronically intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Six Parkinsonian macaques were treated daily with L-DOPA for 3-4 months until they developed LIDs. Three animals were then co-treated with a single dose of 7-NI administered 45 min before each L-DOPA treatment. Dyskinetic MPTP-treated monkeys showed a significant decrease in LIDs compared with their scores without 7-NI treatment (p < 0.05). The anti-Parkinsonian effect of L-DOPA was similar in all three monkeys with and without 7-NI co-treatment. This improvement was significant with respect to the intensity and duration of LIDs while the beneficial effect of L-DOPA treatment was maintained and could represent a promising therapy to improve the quality of life of PD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据